Sandoz ships first medicine in collaboration with Civica Rx to supply US hospitals

PRINCETON, N.J., Nov. 2, 2020 /PRNewswire/ — Sandoz Inc. today announced that it has shipped pantoprazole sodium for injection, 40 mg to Civica Rx to supply the hospitals it serves as part of a multiyear collaboration to help reduce supply shortages, with several other medicines on the way before the end of the year.

Pantoprazole is the first Sandoz medicine to ship to Civica since entering into the agreement in July. It is a proton pump inhibitor indicated in adults for the short-term treatment (7 to 10 days) of gastroesophageal reflux disease (GERD), associated with a history of erosive esophagitis1

Sandoz previously announced it will supply six injectable medicines under the Civica private label to its 1,200 US hospitals. The agreement is being expanded to include an additional medicine to regulate blood pressure, which is frequently used to treat COVID-19 patients in hospitals.

“Our collaboration with Civica is providing certainty for hospitals, doctors and patients who are too often frustrated by shortages of medicines. This is especially important as healthcare providers continue to manage the COVID-19 pandemic,” said Carol Lynch, President, Sandoz Inc. “We are committed to ensuring our medicines are there for the patients who need them when they need them.”

Civica, a non-profit, was founded in 2018 by leading US hospital systems concerned about generic drug shortages and philanthropic organizations passionate about improving healthcare. To date, more than 50 health systems are Civica members, representing more than 1,200 US hospitals and approximately 30 percent of all licensed US hospital beds including acute care. 

“Within a year since our first medication was administered in a hospital ICU, we’ve been able to help millions of patients,” said Martin VanTrieste, president and CEO of Civica. “With Sandoz, we look forward to helping millions more by providing critical medicines that have often been in short supply.”


Pantoprazole sodium is a proton pump inhibitor (PPI) indicated in adults for the following:

  • Short-term treatment (7 to 10 days) of gastroesophageal reflux disease (GERD) associated with a history of Erosive Esophagitis (EE).
  • Pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome.



  • Patients with a known hypersensitivity to any component of the formulation or to substituted benzimidazoles.
  • Patients receiving rilpivirine-containing products.


  • Gastric Malignancy: In adults, symptomatic response to therapy with pantoprazole sodium for injection does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing.
  • Hypersensitivity and Severe Skin Reactions: Anaphylaxis and other serious reactions such as erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis (TEN) have been reported.
  • Injection Site Reactions: Thrombophlebitis is associated with the administration of intravenous pantoprazole.
  • Potential Exacerbation of Zinc Deficiency: Consider zinc supplementation in patients who are prone to zinc deficiency. Caution should be used when other EDTA containing products are also co-administered intravenously.
  • Acute Interstitial Nephritis: Observed in patients taking PPIs.
  • Clostridium difficile-Associated Diarrhea: PPI therapy may be associated with increased risk.
  • Bone Fracture: Long-term and multiple daily dose PPI therapy may
Read more